HCPCS Level II code J9217 identifies leuprolide acetate (for depot suspension), 7.5 mg, a long-acting GnRH agonist formulation used in oncology, urology, and select gynecologic and pediatric indications. As a drug code, it matters nationally because it drives billing for depot injectable therapy in outpatient settings and informs payer coverage, prior authorization workflows, and cost-sharing for patients receiving hormonal suppression therapy. Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.

Readers will learn what the code represents clinically and operationally, which payers’ policies and benchmarks are typically assessed, and what elements affect billing and reimbursement for depot leuprolide products. The publication covers pricing and utilization benchmarks, common payer policy features such as coverage criteria and prior authorization practices, and the clinical contexts where J9217 is applied. It also outlines typical sites of service and the service type tied to the code. Data not present in the input—such as specific payer coverage rules, ICD-10 pairings, and associated taxonomies—is noted as unavailable.